ELISA (enzyme linked immunosorbent assay) kit for detecting endothelial cell specific molecule-1 (ESM-1) of tumour marker
An endothelial cell-specific and kit technology is applied in the field of kits for detecting endothelial cell-specific molecule-1, which can solve the problems of gastric cancer specificity and low specificity, and achieve the effect of improving the early diagnosis rate.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0029] Example 1 The level of ESM-1 nucleic acid in tumor tissue is significantly up-regulated, and the expression of ESM-1 mRNA and protein in gastric cancer tissue is up-regulated:
[0030]In the early stage, we used high-density oligonucleotide chip technology to conduct comprehensive and large-scale research on gastric cancer-related genes, using 42,292 long oligonucleotides (24,000 are reference sequences in the gene database (RefSeqdatabase release 17), The other 24,000 items are EST and Unigene sequence (Unigene build188)) probe chips were studied on the first batch of 46 cases of gastric cancer and 20 cases of non-tumor gastric mucosa, and the differential expression between gastric cancer and adjacent normal tissues and the biological characteristics of gastric cancer were screened out gene. These genes can be used to classify tumors, explore the possible etiology of tumors, predict the prognosis of tumor patients and determine the relevant targets of tumor molecular ...
Embodiment 2
[0071] Example 2 Analysis of the relationship between ESM-1 expression and clinicopathological parameters
[0072] The relationship between the expression of ESM-1 in gastric cancer tissues and the clinicopathological features is shown in Table 7. Chi-square test analysis showed that the positive expression of ESM-1 was more likely to occur in patients with vascular invasion, distant metastasis and Borrmann type IV. The incidence of vascular invasion in patients with positive expression of ESM-1 was 67% (61 / 91), which was significantly higher than 45.3% (29 / 64) in the non-expression group. In addition, the incidence of distant metastasis was also different between the two groups (17.4% vs. 7.5%) (P0.05).
[0073] Table 7 Relationship between ESM-1 expression and clinicopathological parameters (159 patients with gastric cancer)
[0074]
[0075]
[0076] Kaplan-Meier survival analysis was used to evaluate the relationship between the expression of ESM-1 and the clinical...
Embodiment 3
[0082] Example 3: Determination of antibodies and detection conditions for detecting ESM-1
[0083] ESM-1 human recombinant protein (1810EC; R&D Systems, USA) was used as a standard to make a standard curve, and a sensitive and specific paired coating antibody and detection antibody were selected to determine the detection conditions by square array titration.
[0084] Determine the working concentration of the antibody: Dilute the coated antibody with coating solution to four concentrations of 4 μg / mL, 2 μg / mL, 1.3 μg / mL, and 1 μg / mL, and coat the 96-well plate (96-well microtiter plate, Corning company, the U.S.), each concentration was coated with three lines (3 wells per line), and a strong positive antigen was added to the first, second, and third lines of each concentration coating (the concentration of ESM-1 human recombinant protein was 10000pg / ml), weak positive antigen (ESM-1 human recombinant protein concentration is 2000pg / ml) and negative control (normal human se...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com